latest news releases from the newsroom
OXiGENE Reports Preclinical Data for OXi4503 Showing Pronounced Antitumor Activity in Animal Studies in Acute Myeloid Leukemia At the American Association of Cancer Research Annual Meeting
WALTHAM, Mass., April 22, 2009 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN) (XSSE:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, reported data showing that OXi4503 has pronounced antitumor activity when administered as a single agent or in combination with chemotherapy in acute myelogenous leukemia (AML) xenograft models. In the studies, NOD-SCID mice bearing established HL60 xenografts were treated with a series of doses and regimens of either OXi4503 or fosbretabulin administered either as single agents, or combined with araC (standard AML chemotherapy) and evaluated for signs of activity. Results showed that the antitumor activity of OXi4503 against HL60 xenografts is superior to that observed for fosbretabulin, and that HL60 AML xenografts are sensitive to OXi4503 administered as a single agent. In addition, the combination of OXi4503 with araC increased antitumor activity with no apparent increase in toxicity.